König, Nicole
Stetefeld, Henning R.
Dohmen, Christian
Mergenthaler, Philipp
Kohler, Siegfried
Schönenberger, Silvia
Bösel, Julian
Lee, De-Hyung
Gerner, Stefan T.
Huttner, Hagen B.
Schneider, Hauke
Reichmann, Heinz
Fuhrer, Hannah
Berger, Benjamin
Zinke, Jan
Alberty, Anke
Kleiter, Ingo
Schneider-Gold, Christiane
Roth, Christian
Dunkel, Juliane
Steinbrecher, Andreas
Thieme, Andrea
Schlachetzki, Felix
Linker, Ralf A.
Angstwurm, Klemens
Meisel, Andreas
Neumann, Bernhard http://orcid.org/0000-0001-8254-8616
Fuchs, Kornelius
Schalke, Berthold
Vidal, Amelie
Brachaczek, Izabela
Maidhof, Jana
Wenke, Arno
Hagen, Manuel
Rahmig, Jan
Schimmel, Eik
Niesen, Wolf
Fahrendorf, Christine
,
Funding for this research was provided by:
Universität Regensburg
Article History
Received: 26 February 2021
Revised: 1 May 2021
Accepted: 5 May 2021
First Online: 10 May 2021
Declarations
:
: All other authors declare no financial or other conflicts of interest regarding the submitted work. Nicole König reports no disclosures; Henning R. Stetefeld reports no disclosures; Christian Dohmen reports no disclosures; Philipp Mergenthaler is on the Advisory Board of HealthNextGen Inc. and has equity interest in the company; Siegfried Kohler reports no disclosures; Silvia Schönenberger reports no disclosures; Julian Bösel reports personal fees from Medtronic, personal fees from Zoll, personal fees from Boehringer Ingelheim, personal fees from Sedana Medical, and grants from PCORI, outside the submitted work; De-Hyung Lee reports no disclosures; Stefan T. Gerner reports no disclosures; Hagen B. Huttner reports no disclosures; Hauke Schneider reports no disclosures; Heinz Reichmann reports no disclosures; Hannah Fuhrer reports no disclosures; Benjamin Berger received travel grants and/or training expenses from Bayer Vital GmbH, Ipsen Pharma GmbH, Novartis, Biogen GmbH, Merck Serono GmbH, and Genzyme, as well as lecture fees from Ipsen Pharma GmbH, Alexion Pharma Germany GmbH, Merck Serono GmbH, Sanofi Genzyme, and Roche Pharma AG outside the submitted work. Jan Zinke reports no disclosures; Anke Alberty reports no disclosures; Ingo Kleiter reports personal fees from Biogen, personal fees from Novartis, personal fees from Merck, personal fees from Sanofi Genzyme, personal fees from Roche, personal fees from Mylan, personal fees from Alexion, personal fees from Celgene, personal fees from Chugai, and personal fees from IQVIA, outside the submitted work; Christiane Schneider-Gold has received consulting and/or speaker's honoraria from Alexion Pharmaceuticals, Amicus Therapeutics, Bayer Schering, CSL Behring, Grünenthal, Hormosan, Lupin Pharmaceuticals, and TEVA outside the submitted work. Christian Roth reports no disclosures; Juliane Dunkel reports no disclosures; Andreas Steinbrecher reports no disclosures; Andrea Thieme reports no disclosures; Felix Schlachetzki reports no disclosures related to the study and myasthenia gravis specifically; Ralf Linker reports no disclosures; Klemens Angstwurm reports no disclosures; Andreas Meisel reports personal fees from Alexion, personal fees from Grifols, grants from Octapharma, and personal fees from Hormosan, outside the submitted work; Bernhard Neumann reports no disclosures.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Local ethic committees and institutional review boards of the participating centers approved the study based on the central vote of the ethics committee at University of Regensburg (No: 15-101-0259). Due to the retrospective character of the study, patient’s consent was not necessary according to the decisions of the ethic committees and institutional review boards.